research & development > research pipeline


BE features a broad range of promising projects in various stages of development. Some of which are highlighted below:


Haemophilus Influenzae type b conjugated vaccineThe Haemophilus type B conjugate vaccine is a liquid and lyophilised preparation of Haemophilus type B capsular polysaccharide (Polyribosyl-Ribitol-Phosphate {PRP}) covalently bound to tetanus toxoid carrier protein. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell dependent B-cell immune response to the polysaccharide.

DTwP-HBV combination - DTwP-HIB combination DTwP-HBV-HIB combination - is under clinical development process. The DTwP-HBV combination are currently undergoing Phase-III human clinical trials.

Meningitis vaccine This vaccine is under research and development in which polysaccharides developed from serotypes A, C, W & Y will be mixed to formulate the vaccine. Already serotype A and C polysaccharides have been standardized.